GNPTCD19SPA-0001

N/A

Report date: 2025/01/26 15:51:42

Base Information

Drug NameGNPTCD19SPA-0001
Drug Alias Nameanti-CD19 CAR T-cell therapy (Genepeutic Bio/Mahidol University/Thailand Center of Excellence for Life Sciences)2nd generation CD19 CAR T-cellsanti-CD19 allogeneic CAR-T cell therapy(Genepeutic Bio/Mahidol University/Thailand Center of Excellence for Life Sciences)GNPTCD19SPA-0001
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryThailand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenepeutic Bio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGenepeutic Bio Co LtdThailand Center Of Excellence For Life Sciences (OKMD)Mahidol University
Inactive CompaniesN/A
Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A